MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes 90 each of 4 and 8 unit cartridges, which it says accounts for nearly 25% of Afrezza units dispensed on a weekly basis.
According to the company, “This new package is intended to simplify physician prescribing of Afrezza and allow patients greater dose flexibility in managing their diabetes, while potentially reducing the cost burden of multiple copays.”
The company also said that it has converted its sales force from contract to a larger in-house team and added more diabetes nurse educators. MannKind took over distribution of Afrezza in August 2016, 8 months after Sanofi announced that it would return the rights to the product.
MannKind CEO Matthew Pfeffer commented, “The new package, along with our new sales force expansion and nurse educator model, will enable us to make a stronger impact in how we market Afrezza without dramatically increasing our cost structure. Additionally, our commercial organization has several direct-to-consumer and digital media initiatives deploying in the next few months that will further expand our promotional efforts.”
Read the MannKind press release.
